Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:58:56.241Z.
Calculation as of: 2026-10-06T20:58:56.241Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 06d607300f47343d1cd5625897ab9451fc86a9e564f014de5145334d904f0225
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-05-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tempest Therapeutics, Inc.
Market Cap
$12.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.78M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.06M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.20M
EV/EBITDA Ratio
N/A
TTM Avg
116.01x
3Y Avg
116.01x
5Y Avg
116.01x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. (TPST) | $12.58M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | 116.01x | 116.01x | 116.01x |
| Biofrontera Inc. (BFRI)vs › | $11.93M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2015-05-11 | 21904.41x |
| 2015-05-08 | 20168.82x |
| 2015-05-07 | 20200.24x |
| 2015-05-06 | 19218.57x |
| 2015-05-05 | 19202.86x |
| 2015-05-04 | 19933.22x |
| 2015-05-01 | 19870.39x |
| 2015-04-30 | 19418.83x |
| 2015-04-29 | 21079.81x |
| 2015-04-28 | 21558.86x |
| 2015-04-27 | 22234.25x |
| 2015-04-24 | 23859.89x |
| 2015-04-23 | 24291.82x |
| 2015-04-22 | 23427.95x |
| 2015-04-21 | 23616.43x |
| 2015-04-20 | 23412.25x |
| 2015-04-17 | 24079.78x |
| 2015-04-16 | 24802.29x |
| 2015-04-15 | 24731.61x |
| 2015-04-14 | 24802.29x |
| 2015-04-13 | 25022.18x |
| 2015-04-10 | 24951.50x |
| 2015-04-09 | 23066.70x |
| 2015-04-08 | 22430.58x |
| 2015-04-07 | 23223.77x |
| 2015-04-06 | 26263.01x |
| 2015-04-02 | 27519.54x |
| 2015-04-01 | 24448.89x |
| 2015-03-31 | 27260.38x |
| 2015-03-30 | 29969.78x |
| 2015-03-27 | 34124.20x |
| 2015-03-26 | 37909.51x |
| 2015-03-25 | 39095.36x |
| 2015-03-24 | 41969.68x |
| 2015-03-23 | 37414.75x |
| 2015-03-20 | 36872.87x |
| 2015-03-19 | 35317.91x |
| 2015-03-18 | 33362.43x |
| 2015-03-17 | 33016.88x |
